Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
John J McNeillRory WolfeRobyn L WoodsAndrew M TonkinGeoffrey A DonnanMark R NelsonChristopher M ReidJessica E LockeryBrenda KirpachElsdon StoreyRaj C ShahJeff D WilliamsonKaren L MargolisMichael E ErnstWalter P AbhayaratnaNigel StocksSharyn M FitzgeraldSuzanne G OrchardRuth E TrevaksLawrence J BeilinColin I JohnstonJoanne RyanBarbara RadziszewskaMichael JelinekMobin MalikCharles B EatonDonna BrauerGeoff CloudErica M WoodSuzanne E MahadySuzanne SatterfieldRichard GrimmAnne M Murraynull nullPublished in: The New England journal of medicine (2018)
The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .).
Keyphrases
- cardiovascular events
- cardiovascular disease
- low dose
- coronary artery disease
- high dose
- physical activity
- middle aged
- atrial fibrillation
- quality improvement
- type diabetes
- cardiovascular risk factors
- community dwelling
- double blind
- clinical trial
- percutaneous coronary intervention
- study protocol
- acute coronary syndrome